Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-puff_SE_2024
2024-519131-42-02Phase 4Authorised
- Sponsor
- Semmelweis University
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fentanyl in cancer pain and breakthrough cancer pain (BTcP), sponsored by Semmelweis University. Primary endpoint: Responder rate on NPRS scale. Planned start Oct 2025; status: authorised.
02
Drugs
fentanyl
03
Conditions
cancer painbreakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on 2024-519131-42-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519131-42-02.